AACR 2020 – New blood-based test for prostate cancer shows >92% accuracy


  • Elena Riboldi — Agenzia Zoe
  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A newly developed mRNA-based prostate cancer (PCa) liquid biopsy test has a diagnostic accuracy of >92%.
  • This accuracy is significantly higher than that of the PSA test.

Why this matters

  • PCa is the most common noncutaneous cancer in men.
  • Reliable PCa biomarkers are an unmet need.

Study design

  • Using a publicly available PCa transcriptome sets, a putative PCa signature was identified.
  • Candidate genes were assessed using PCa and normal prostate cell lines and validated in tumor tissue and The Cancer Genome Atlas Prostate Adenocarcinoma (TCGA-PRAD) dataset.
  • Using 2 datasets (PCa, n=132; benign prostatic hyperplasia, n=44; controls, n=55) and classification algorithm analyses, an artificial intelligence PCa model was constructed.
  • Funding: Wren Laboratories.

Key results

  • Transcriptomic analysis identified a 27-gene blood signature for PCa.
  • Candidate genes were detectable and upregulated in PCa cell lines and tumor tissue.
  • Blood and tumor tissue gene expression significantly correlated (r=0.56).
  • A 0-100 score, based on normalized algorithmically analyzed gene expression, was developed (score ≥20=positive).
  • The diagnostic accuracy of the test (PROSTest) was 92.4%; sensitivity and specificity were 94.4% and 89.7%, respectively.
  • The score significantly decreased after surgical resection and increased during biochemical recurrence (biochemical recurrence detection rate, 96%).
  • PSA accuracy (>10 ng/mL) in PCa diagnosis was 48% (P<.0001>